http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
환경시료로부터 미량 페놀류의 분석을 위한 isoButoxycarbonyl 유도체화 분석방법 적용 및 최적화
김협,홍종기,김용화,김경래 한국환경독성학회 2002 환경독성보건학회지 Vol.17 No.1
Eleven phenols including two chlorophenols, eight alkylphenols and bisphenol A were derivatized with isobutylchlomformate to form their isobutoxycarbonyl derivatives. Standard phenol mixture was concentrated for the isebutoxycarbonyl (isoBOC) derivatization and analysed by gas chromatography/mass spectrometry (GC/MS). The recoveries of the derivatization method of alkylphenols, chlorophenols, and bisphenol A were calculated by gas chromatography/mass spectrometry -selected ion monitoring mode using two work-up methods for comparison; shaking and heating method. The linear detector responses were obtained in the concentration range of 5 -400 ng, with correlation coefficients varying from 0.9755-0,9981. Recoveries of the alkylphenols, chlorophenols, and bisphenol A were determined by gas chromatography /mass spectrometry -selected ion monitoring mode using two work-up methods for comparison; the US-EPA method and the isoBOC derivatization method. Eleven phenols in water samples were extracted with dichloromethane and then concentrated. Also, solid-phase extraction (SPE) with XAD-4 and subsequent conversion to isobutoxymbony derivatives for sensitive analysis with the selected ion-monitoring (SIM) mode. The recoveries were 85.1~109.9% and 90.3~126.6% for the US-EPA method and the isoBOC derivatization method, respectively. The method detection limits of bisphenol A for SIM were 0.732 ㎍/ℓ and 0.002 ㎍/ℓ for the two methods above, respectively.
Kim, Mi Na,Kim, Hyon-Suk,Kim, Ja Kyung,Kim, Beom Kyung,Kim, Seung Up,Park, Jun Yong,Kim, Do Young,Ahn, Sang Hoon,Han, Kwang-Hyub The Korean Academy of Medical Sciences 2016 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.31 No.9
<P>Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for prediction of treatment response in HCV infection. We analyzed serum from 92 patients with HCV infection who had been treated with pegylated interferon and ribavirin. HCV Ag levels were determined at baseline in all enrolled patients and at week 4 in 15 patients. Baseline HCV Ag levels showed good correlations with HCV RNA (<I>r</I> = 0.79, <I>P</I> < 0.001). Mean HCV Ag levels at baseline were significantly lower in patients with a sustained virologic response (SVR) than in those with a non SVR (relapse plus non responder) based on HCV RNA analysis (2.8 log<SUB>10</SUB>fmol/L vs. 3.27 log<SUB>10</SUB>fmol/L, <I>P</I> = 0.023). Monitoring of the viral kinetics by determination of HCV RNA and HCV Ag levels resulted in similarly shaped curves. Patients with undetectable HCV Ag levels at week 4 had a 92.3% probability of achieving SVR based on HCV RNA assay results. The HCV Ag assay may be used as a supplement for predicting treatment response in HCV infection, but not as an alternative to the HCV RNA assay.</P>
Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis
Kim, Do Young,Kim, Jie Hyun,Chon, Chae Yoon,Han, Kwang-Hyub,Ahn, Sang Hoon,Kim, Ja Kyung,Paik, Yong Han,Lee, Kwan Sik,Moon, Young Myoung Wiley-Blackwell Publishing 2005 Liver International Vol. No.
<P>AbstractPurpose</P><P>Rapid and accurate diagnosis of spontaneous bacterial peritonitis (SBP) is mandatory for timely treatment in cirrhotic patients. The purpose of this study was to assess the usefulness of two different reagent strips, the UriSCAN and the Multistix10SG, for the rapid bedside diagnosis of SBP.</P><P>Methods</P><P>A total of 75 paracenteses in 53 cirrhotic patients with ascites were performed. All ascitic fluid was analyzed with the two reagent strips, and compared with the manual cell count with differential and ascitic fluid culture. SBP was defined as an ascitic polymorphonuclear cell count ≥250/mm<SUP>3</SUP>.</P><P>Results</P><P>SBP was diagnosed in 18 of the 75 samples. If we considered the positive UriSCAN result of 2 or more, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were all 100%. When we considered the positive UriSCAN result of 3, the sensitivity, specificity, PPV, and NPV were 67%, 100%, 100%, and 89%, respectively. When we considered the positive Multistix10SG result of 3, the sensitivity, specificity, PPV, and NPV were 50%, 100%, 100%, and 87%, respectively.</P><P>Conclusion</P><P>Urine reagent strip might be useful for rapid and accurate diagnosis of SBP in cirrhotic patients with ascites.</P>
Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B
Kim, Do Young,Kim, Seung Up,Ahn, Sang Hoon,Park, Jun Yong,Lee, Jung Min,Park, Young Nyun,Yoon, Ki Tae,Paik, Yong Han,Lee, Kwan Sik,Chon, Chae Yoon,Han, Kwang-Hyub Springer-Verlag 2009 Digestive diseases and sciences Vol.54 No.8
Kim, Hyub,Hong, Jong-Ki,Kim, Yong-Hwa,Kim, Kyoung-Rae The Pharmaceutical Society of Korea 2003 Archives of Pharmacal Research Vol.26 No.9
The alkylphenols, chlorophenols, and bisphenol A were determined by gas chromatography/mass spectrometry-selected ion monitoring (GC/MS-SIM) followed by two work-up methods for comparison: isobutoxycarbonyl (isoBOC) derivatization and tert-butyldimethylsilyl (TBDMS) derivatization. Eleven endocrine disrupting chemicals (EDCs) of phenols in biological samples were extracted with acetonitrile and then the acetonitrile layer underwent freezing filtration 6$0^{\circ}C$ for 2 hours. Solid-phase extraction (SPE) was used with XAD-4 and subsequent conversion to isoBOC or TBDMS derivatives for sensitivity analysis with the GC/MS-SIM mode. For isoBOC derivatization and TBDMS derivatization the recoveries were 92.3∼150.6% and 93.8∼108.3%, the method detection limits (MDLs) of bisphenol A for SIM were 0.062 $\mu$ g/kg and 0.010 $\mu$ g/kg, and the SIM responses were linear with the correlation coefficient varying by 0.9755∼0.9981 and 0.9908∼0.9996, respectively. When these methods were applied to mackerel samples, the concentrations of the 11 phenol EDCs were below the MDL.
Kim, Yong-Hyub,Song, Sang-Yun,Shim, Hyun-Jeong,Chung, Woong-Ki,Ahn, Sung-Ja,Yoon, Mee Sun,Jeong, Jae-Uk,Song, Ju-Young,Nam, Taek-Keun The Korean Society for Radiation Oncology 2015 Radiation Oncology Journal Vol.33 No.1
Purpose: To evaluate treatment outcomes and determine prognostic factors in patients with esophageal cancer treated with esophagectomy after neoadjuvant chemoradiotherapy (NCRT) Materials and Methods: We retrospectively evaluated 39 patients with esophageal cancer who underwent concurrent chemoradiotherapy followed by esophagectomy between 2002 and 2012. Initial clinical stages of patients were stage IB in 1 patient (2.6%), stage II in 5 patients (12.9%), and stage III in 33 patients (84.6%). Results: The median age of all the patients was 62 years, and the median follow-up period was 17 months. The 3-year overall survival (OS) rate was 33.6% in all the patients. The 3-year locoregional recurrence-free survival (LRFS) rate was 33.7%. In multivariate analysis with covariates of age, the Eastern Cooperative Oncology Group performance status, hypertension, diabetes mellitus, tumor length, clinical response, clinical stage, pathological response, pathological stage, lymphovascular invasion, surgical type, and radiotherapy to surgery interval, only pathological stage was an independent significant prognostic factor affecting both OS and LRFS. The complications in postoperative day 90 were pneumonia in 9 patients, anastomotic site leakage in 3 patients, and anastomotic site stricture in 2 patients. Postoperative 30-day mortality rate was 10.3% (4/39); the cause of death among these 4 patients was respiratory failure in 3 patients and myocardial infarction in one patient. Conclusion: Only pathological stage was an independent prognostic factor for both OS and LRFS in patients with esophageal cancer treated with esophagectomy after NCRT. We could confirm the significant role of NCRT in downstaging the initial tumor bulk and thus resulting in better survival of patients who gained earlier pathological stage after NCRT.
Kim, Seung Up,Seo, Yeon Seok,Lee, Han Ah,Kim, Mi Na,Lee, Yu Rim,Lee, Hye Won,Park, Jun Yong,Kim, Do Young,Ahn, Sang Hoon,Han, Kwang-Hyub,Hwang, Seong Gyu,Rim, Kyu Sung,Um, Soon Ho,Tak, Won Young,Kweon Elsevier 2019 Journal of hepatology Vol.71 No.3
<P><B>Background & Aims</B></P> <P>It is currently unclear which antiviral agent, entecavir (ETV) or tenofovir disoproxil fumarate (TDF), is superior for improving prognosis in patients with chronic hepatitis B (CHB). Here, we assessed the ability of these 2 antivirals to prevent liver-disease progression in treatment-naïve patients with CHB.</P> <P><B>Methods</B></P> <P>From 2012 to 2014, treatment-naïve patients with CHB who received ETV or TDF as a first-line antiviral agent were recruited from 4 academic teaching hospitals. Patients with decompensated cirrhosis or hepatocellular carcinoma (HCC) at enrollment were excluded. Cumulative probabilities of HCC and death or orthotopic liver transplant (OLT) were assessed.</P> <P><B>Results</B></P> <P>In total, 2,897 patients (1,484 and 1,413 in the ETV and TDF groups, respectively) were recruited. The annual HCC incidence was not statistically different between the ETV and TDF groups (1.92 <I>vs</I>. 1.69 per 100 person-years [PY], respectively; adjusted hazard ratio [HR] 0.975 [<I>p</I> = 0.852] by multivariate analysis). Propensity score (PS)-matched and inverse probability of treatment weighting (ITPW) analyses yielded similar patterns of results (HR 1.021 [<I>p</I> = 0.884] and 0.998 [<I>p</I> = 0.988], respectively). The annual incidence of death or OLT was not statistically different between the ETV and TDF groups (0.52 <I>vs</I>. 0.53 per 100 PY, respectively; adjusted HR 1.202 [<I>p</I> = 0.451]). PS-matched and ITPW analyses yielded similar patterns of results (HR 1.248 [<I>p</I> = 0.385] and 1.239 [<I>p</I> = 0.360], respectively). These findings were consistently reproduced in patients with compensated cirrhosis (all <I>p</I> >0.05).</P> <P><B>Conclusions</B></P> <P>The overall prognosis in terms of HCC and death or OLT was not statistically different between the ETV and TDF groups. Further studies are needed to validate our results.</P> <P><B>Lay summary</B></P> <P>It is currently unclear which antiviral agent, entecavir or tenofovir disoproxil fumarate, is superior for improving prognosis in patients with chronic hepatitis B virus infection. In this analysis we found that there was no difference in terms of overall prognosis, including risk of hepatocellular carcinoma, death, or the need for a liver transplant, in patients receiving either antiviral.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The hepatocellular carcinoma risk was not statistically different between the ETV and TDF groups. </LI> <LI> The death or liver transplant risk was not statistically different between the 2 groups. </LI> <LI> These results were consistently reproduced after adjusting for confounding variables. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Variability in liver stiffness values from different intercostal spaces
Kim, Seung Up,Kim, Ja Kyung,Park, Jun Yong,Ahn, Sang Hoon,Lee, Jung Min,Baatarkhuu, Oidov,Choi, Eun Hee,Han, Kwang-Hyub,Chon, Chae Yoon,Kim, Do Young Blackwell Publishing Ltd 2009 Liver international Vol.29 No.5
<P>Abstract</P><P><I>Aim</I>: To investigate the variability in liver stiffness measurement (LSM) values from the fifth, sixth and seventh intercostal space (ICS) and examine whether LSM better predicts significant fibrosis (F2–4) and cirrhosis when LSM is performed at the same site as liver biopsy (LB). <I>Methods</I>: This study enrolled 91 consecutive patients with hepatitis B virus (HBV)-related chronic liver disease (CLD) who underwent both LB and LSM between September 2007 and January 2009. <I>Results</I>: The mean age of the patients was 45.4 years (66 men and 25 women). F1 fibrosis was noted in 12 patients (13.2%), F2 in 28 (30.7%), F3 in 15 (16.5%) and F4 in 36 (39.6%). The mean LSM values from the fifth, sixth and seventh ICS were 11.6, 11.1 and 10.9 kPa respectively. The mean LSM value from the same site as LB was 11.0 kPa. An interclass correlation analysis showed no significant difference in LSM values from the fifth, sixth and seventh ICS and the same site as LB. The area under the receiver operating characteristic curves of LSM values from the fifth, sixth and seventh ICS and the same site as LB for predicting significant fibrosis were 0.815, 0.838, 0.818 and 0.837, respectively, and those for cirrhosis were 0.919, 0.916, 0.907 and 0.913, respectively, with all overlapping confidence intervals. <I>Conclusions</I>: Any LSM value from the fifth, sixth or seventh ICS can predict significant fibrosis and cirrhosis with considerable accuracy without statistical differences regardless of correspondence with LB site in patients with HBV-related CLD.</P>